Core Insights - Eli Lilly's oral weight loss drug orforglipron has shown significant progress in late-stage clinical trials, demonstrating its ability to help patients maintain weight loss after switching from injectable treatments [1][3] - The FDA has received a submission for orforglipron's approval, which could provide a non-injection long-term weight management solution for obesity patients [1] - The oral weight loss drug market is expected to be dominated by Eli Lilly and Novo Nordisk, with Eli Lilly potentially capturing a significant share of the maintenance patient market [2] Clinical Trial Results - The ATTAIN-MAINTAIN phase 3 clinical trial included over 300 obesity patients who previously received 72 weeks of treatment with Wegovy or Zepbound injections, followed by a 52-week observation period after switching to orforglipron or a placebo [3] - The trial met its primary endpoint, showing that orforglipron significantly outperformed the placebo in maintaining weight after the injection treatment plateau, with patients switching from Wegovy regaining an average of only 2 pounds, while those switching from Zepbound regained about 11 pounds [3] Competitive Landscape - Analysts believe the trial results provide Eli Lilly with a unique opportunity to capture revenue from patients who have been on long-term treatment with Novo Nordisk's semaglutide products [4] - Unlike Novo Nordisk's oral medications, orforglipron is not a peptide drug, making it easier for the body to absorb and potentially offering better patient compliance and long-term convenience [4] Safety and Market Share Projections - Safety data for orforglipron aligns with previous studies, with gastrointestinal symptoms being the most common side effects, typically mild to moderate in severity [5] - Discontinuation rates due to side effects were low, with 4.8% for the Wegovy switch group and 7.2% for the Zepbound switch group, compared to 7.6% and 6.3% for the placebo groups, respectively [5] - Goldman Sachs analysts project that the oral weight loss drug market will reach approximately $22 billion by 2030, with orforglipron expected to capture about 60% of this market share [6]

Core Insights - The article discusses the positive outlook for international stocks in 2026, highlighting robust earnings, economic growth, and attractive valuations compared to the S&P 500 [2] - It emphasizes the potential for diversification away from the tech-heavy S&P 500, suggesting that international stocks are an appealing alternative for investors [2] Economic Context - Several international economies are expected to implement significant fiscal stimulus, which is anticipated to enhance stock market performance [3] - Germany's fiscal spending is projected to increase, with a focus on a €500 billion infrastructure fund and raising defense spending to 3.5% of GDP by 2029 [3] - Japan has announced its largest stimulus package since the pandemic, totaling ¥21.3 trillion (approximately $136 billion), aimed at inflation relief for key industries such as AI, semiconductors, and shipbuilding [4] Investment Methodology - The list of the 10 Best Non-US Stocks to Buy According to Hedge Funds was curated using the Finviz stock screener, WSJ, and Insider Monkey's Q3 2025 database [6] - Stocks were ranked based on the number of hedge fund holders, with market capitalization data sourced from the Wall Street Journal [6] Stock Highlights - **Shell plc (NYSE:SHEL)**: - Market Capitalization: $204.91 billion - Number of Hedge Fund Holders: 48 - Announced a final investment decision on its waterflood project at Kaikias field, expected to increase recoverable resource volumes by approximately 60 million metric barrels of oil equivalent [8][10] - Wall Street maintains a bullish outlook, with a Buy rating and a price target of £2,686.5 from Goldman Sachs and Barclays [12] - **Novo Nordisk A/S (NYSE:NVO)**: - Market Capitalization: $224.04 billion - Number of Hedge Fund Holders: 50 - Received a positive opinion from the European Medicines Agency for a higher dosage of Wegovy, showing improved weight loss results of around 20.7% at 72 weeks [14][15] - The stock has a cautious outlook from Wall Street, with a Hold rating and a price target increase from $47 to $54 by HSBC [17]

Novo Nordisk has halted the development of any drug not tied to diabetes or obesity. That narrower focus is meant to clear the way for two new launches next year, including an oral version of Wegovy https://t.co/w64rYoowC4 ...

Core Viewpoint - Eli Lilly's oral weight loss medication has shown promising results in maintaining weight loss for patients transitioning from injectable treatments, indicating its potential as a non-injection maintenance therapy in the GLP-1 market [1][7]. Group 1: Clinical Trial Results - The Phase 3 trial tracked over 300 obese patients who previously received 72 weeks of treatment with Wegovy or Zepbound, followed by a 52-week period of either the oral medication or a placebo [2][8]. - Patients switching from Wegovy to the oral medication regained an average of about 2 pounds, while those switching from Zepbound regained approximately 11 pounds by the end of the study [2][8]. - The oral medication significantly outperformed the placebo in maintaining weight loss among patients whose weight loss had plateaued during previous injectable treatments [2][8]. Group 2: Market Potential - Analysts predict that by 2030, the oral medication market will capture 24% of the global weight loss drug market, estimated at $95 billion, translating to about $22 billion [5][11]. - Eli Lilly's oral medication is expected to hold a 60% share of the daily oral segment, approximately $13.6 billion, while Novo Nordisk's oral semaglutide is projected to capture 21% of this segment, around $4 billion [6][11]. Group 3: Safety and Efficacy - The overall safety and tolerability of the oral medication align with previous late-stage studies, with gastrointestinal side effects being the most common and generally mild to moderate [4][10]. - Approximately 4.8% of patients switching from Wegovy and 7.2% from Zepbound discontinued treatment due to side effects, compared to 7.6% and 6.3% for those on placebo [10]. - No liver safety issues were observed, and the complete results of the ATTAIN-MAINTAIN trial will be presented at an upcoming medical conference and published in a peer-reviewed journal next year [10].

Group 1 - Novo Nordisk and Intuitive Surgical are both leaders in the healthcare sector but operate in different areas, with Novo Nordisk focusing on pharmaceutical drugs and Intuitive Surgical on robotic-assisted surgery devices [1] - Both companies have faced challenges this year, resulting in below-average stock-market performances, but there is potential for recovery in the coming years [2] Group 2 - Novo Nordisk's financial results have not met investor expectations, with a decline in top-line growth and a lowered outlook due to losing ground in the GLP-1 market, which is crucial for its revenue [4] - The company is expected to launch new products, including CagriSema, which, despite not meeting the target of 25% mean weight loss, achieved a competitive 22.7%, potentially aiding its position in the crowded GLP-1 market [5] - Recent and pending label expansions for semaglutide, including new approvals for reducing cardiovascular event risks and treating metabolic dysfunction-associated steatohepatitis, could enhance Novo Nordisk's sales growth [6] - Novo Nordisk's sales increased by 12% year over year to 229.9 billion Danish kroner ($36.2 billion) in the first nine months of the year, while net profit rose by 4% to 75.5 billion DKK ($11.9 billion) [7] Group 3 - Intuitive Surgical is expected to maintain its leadership in the robotic-assisted surgery niche despite facing increased competition [8] - Both Novo Nordisk and Intuitive Surgical have the potential to be long-term winners, with investment choices depending on individual risk tolerance [8]

Core Insights - Eli Lilly's obesity pill, orforglipron, has shown promising results in maintaining weight loss for patients transitioning from injections like Zepbound and Wegovy in a late-stage trial [1][3][4] Group 1: Trial Results - The phase three trial involved over 300 patients who had previously taken Wegovy or Zepbound for 72 weeks, followed by a 52-week period where they were randomized to receive either the pill or a placebo [4] - Patients switching from Wegovy regained an average of only 2 pounds, while those switching from Zepbound regained about 11 pounds by the end of the trial [5] - The pill met its primary goal of demonstrating superior weight loss maintenance compared to placebo among patients who had plateaued while on injections [4] Group 2: FDA Approval and Market Potential - Eli Lilly has filed for FDA approval of orforglipron, which has received a priority review voucher that could expedite the review process [2] - Analysts suggest that positive trial results could allow Eli Lilly to capture market share from Novo Nordisk's semaglutide products, potentially impacting the competitive landscape [7] Group 3: Safety and Tolerability - The safety profile of the pill was consistent with previous studies, with common side effects being mild-to-moderate gastrointestinal issues [8] - Discontinuation rates due to side effects were 4.8% for those switching from Wegovy and 7.2% for those switching from Zepbound [9] Group 4: Market Forecast - Analysts predict that oral medications will capture a 24% share of the global weight loss drug market by 2030, valued at approximately $95 billion [12] - Eli Lilly's pill is expected to hold a 60% share of the daily oral segment, translating to around $13.6 billion, while Novo Nordisk's oral semaglutide is projected to have a 21% share [13]

Core Insights - Eli Lilly and Novo Nordisk are leading companies in the GLP-1 weight loss market, with strong long-term growth prospects due to their innovative products [1] - Eli Lilly's stock has increased by 35% over the past year, while Novo Nordisk's stock has decreased by 53% [2] Eli Lilly - Eli Lilly has achieved a market capitalization of over $1 trillion, becoming the first healthcare company to reach this milestone [4] - The company's GLP-1 drugs, Mounjaro and Zepbound, generated $25 billion in revenue in the first nine months of the year, accounting for more than half of its total sales of $46 billion [5] - Zepbound has shown superior effectiveness in weight loss compared to Novo Nordisk's Wegovy, with an average weight loss of 20.2% versus 13.7% in a 72-week trial [6] - Eli Lilly's stock has increased by over 570% in the past five years, indicating strong growth potential [7] Novo Nordisk - Novo Nordisk has faced challenges, including a change in leadership and a reduction in guidance due to competition from compounded drug versions, leading to a decline in its stock price [8] - Despite recent difficulties, there is optimism for a turnaround, as the stock is currently trading at a low valuation of 14 times its trailing earnings, compared to Eli Lilly's P/E ratio of over 50 [10] - The current lower expectations for Novo Nordisk may present a buying opportunity for investors [10]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are highlighted, with significant implications for global power grids and electricity supply [2][3] Investment Opportunity - A specific company is positioned as a critical player in the AI energy sector, owning essential energy infrastructure assets that will benefit from the increasing energy demands of AI data centers [3][7] - This company is not a chipmaker or cloud platform but is described as a "toll booth" operator in the AI energy boom, collecting fees from energy exports [5][6] Market Position - The company is noted for its unique capabilities in executing large-scale engineering, procurement, and construction (EPC) projects across various energy sectors, including nuclear energy [7][8] - It is completely debt-free and has a significant cash reserve, amounting to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened with debt [8][10] Growth Potential - The company also holds a substantial equity stake in another AI-related venture, providing investors with indirect exposure to multiple growth opportunities in the AI sector [9][10] - The stock is described as undervalued, trading at less than seven times earnings, which presents a compelling investment case given its ties to the burgeoning AI and energy markets [10][11] Industry Trends - The article discusses the broader trends of onshoring driven by tariffs and the surge in U.S. LNG exports, indicating a favorable environment for the company's operations [14] - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, reinforcing the importance of investing in AI-related companies [12]

Group 1 - GreensKeeper Asset Management reported a +4.0% gain for its Value Fund in Q3 2025, with a year-to-date return of +0.2% net of fees and expenses [1] - The US dollar negatively impacted performance by -3.7% year-to-date, while the market rally was primarily driven by AI, crypto, and speculation [1] - The fund's top 5 holdings can be reviewed to identify its best investment picks for 2025 [1] Group 2 - Novo Nordisk A/S (NYSE:NVO) experienced a one-month return of -0.08% and a significant 53.79% loss in value over the last 52 weeks, closing at $48.96 per share with a market capitalization of $217.553 billion on December 16, 2025 [2] - Novo Nordisk A/S was the second-largest detractor for the fund in Q3 2025, with a decline of -19.6%, attributed to lowered guidance due to factors such as competition and slower market expansion for obesity treatments [3] - Despite being held by 50 hedge fund portfolios at the end of Q3, the company is not among the 30 most popular stocks among hedge funds, with the potential for AI stocks being viewed as offering greater upside potential [4]

Novo Nordisk wants to grow its direct channels, which currently account for a tenth of its weight-loss jab prescriptions in America. The drugmaker is revising its pricing, too https://t.co/IuSb2NdVsW ...